News
| 3 min read
The science being built right now in discovery labs is what acquirers are already looking for.
| 3 min read
Voyager Therapeutics’ promising toxicology data in non-human primates suggests their proprietary capsid technology could deliver long-lasting results in Alzheimer’s disease.
| 2 min read
The deal brings a first-in-class anti-CD122 antibody with early clinical validation in vitiligo and celiac disease into argenx's pipeline.
| 4 min read
Positive results in metabolic disease, a possible vaccine to treat the current Ebola outbreak, new cancer drug targets, and more led the news this week.
| 6 min read
Phase Advance is using mechanistic virtual patient models to predict how LEAF4Life's hypoxia-targeting therapy could perform across multiple indications.
| 3 min read
A new blood test focusing on KRAS mutations found evidence of pancreatic cancer recurrence before standard testing.
| 4 min read
Results from Johns Hopkins show a synthetic peptide vaccine was safe and activated mutant-KRAS-specific T cells in 90 percent of participants, offering an early signal that cancer interception may be possible before disease develops.
| 3 min read
Researchers find that infant airway tissue actively shapes the immune response to RSV, suggesting future therapies should target both the virus and inflammation.
| 4 min read
A synthetic flavone restored vaginal tissue in a preclinical model, offering a potential nonsteroidal treatment for genitourinary syndrome of menopause.
| 4 min read
Psychedelic acquisitions, clinical trial updates, and more led the news this week.
| 5 min read
Aurion Biotech's manufacturing approach to unmodified allogeneic corneal endothelial cells offers a set of hard-won lessons for a cell therapy field still working out how to get from proof-of-concept to broad patient access.
| 3 min read
A new platform combines engineered viral vectors with the brain's glymphatic system to improve gene delivery to glial cells implicated in multiple neurological disorders.
